NVCT Stock Analysis: Nuvectis Pharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 632m USD | 12M Return: 224.2% | US67080T1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.70M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 4.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nuvectis Pharma, Inc. (NVCT) is a U.S.-based, clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions with unmet medical need. Its lead candidate, NXP900, is a small molecule inhibitor of c-Src and YES1 kinases currently in a Phase 1b clinical trial for solid tumors. The company was incorporated in 2020 (originally as Centry Pharma, Inc.) and is headquartered in Fort Lee, New Jersey, with its common stock listed on NASDAQ since early 2022.
As a clinical-stage biotech, Nuvectis operates under a typical biopharma business model in which it invests heavily in R&D with no current commercial product revenue, relying instead on capital markets and partnerships to fund trials until potential regulatory approval and commercialization. The focus on kinase inhibitors targeting validated oncogenic drivers reflects a broader industry shift toward precision oncology, where therapies are designed to selectively address specific genetic or molecular alterations in tumors.
- NXP900 Phase 1b data readout in solid tumor patients
- FDA orphan drug designation boosts NXP900 development pathway
- Cash runway extension through equity offering risks shareholder dilution
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.87 > 0.02 and ΔFCF/TA -41.24 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.87 > 3% & CFO -19.5m > Net Income -27.8m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.5m) vs 12m ago 9.87% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 99.22%; Δ -99.22% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.41 (Total Current Assets 22.4m - Total Current Liabilities 13.3m) / Total Assets 22.4m |
| B: -5.04 (Retained Earnings -112.8m / Total Assets 22.4m) |
| C: -1.17 (EBIT TTM -28.9m / Avg Total Assets 24.7m) |
| D: 0.68 (Book Value of Equity 9.08m / Total Liabilities 13.3m) |
| Altman-Z'' = -20.90 = D |
As of August 19, 2026, the stock is trading at USD 20.91 with a total of 215,224 shares traded. Over the past week, the price has changed by +7.73%, over one month by +15.97%, over three months by +101.06% and over the past year by +224.19%.
Current recommended Stop Loss: 19.20 (which is 8.2% or 1.2 ATR below the current price).
Nuvectis Pharma has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy NVCT.
- StrongBuy: 2
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 34.2 | 63.6% |
P/B = 67.6958
Revenue TTM = 0.0 USD
EBIT TTM = -28.9m USD
EBITDA TTM = -28.9m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 610.2m USD (632.4m + (null Debt) - CCE 22.2m)
Interest Coverage Ratio = unknown (Ebit TTM -28.9m / Interest Expense TTM 0.0)
EV/FCF = -31.28x (Enterprise Value 610.2m / FCF TTM -19.5m)
FCF Yield = -3.20% (FCF TTM -19.5m / Enterprise Value 610.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 27.27 (Enterprise Value 610.2m / Total Assets 22.4m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -22.8m (EBIT -28.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 22.4m / Total Current Liabilities 13.3m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -28.9m)
Debt / FCF = unknown (Net Debt none / FCF TTM -19.5m)
Total Stockholder Equity = 16.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -112.8% (out of range, set to none)
RoE = -169.5% (Net Income TTM -27.8m / Total Stockholder Equity 16.4m)
RoCE = -317.9% (out of range, set to none) (EBIT -28.9m / Capital Employed (Total Assets 22.4m - Current Liab 13.3m))
RoIC = -251.1% (out of range, set to none) (NOPAT -22.8m / Invested Capital 9.08m)
WACC = 7.09% (E(632.4m)/V(632.4m) * Re(7.09%) + (debt-free company))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.00 | Cagr: 16.78%
[DCF] Fair Price = unknown (Cash Flow -19.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.62 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.23 | Chg30d=+11.72% | Revisions=+40% | Analysts=5
EPS current Year (2026-12-31): EPS=-1.00 | Chg30d=+1.38% | Revisions=+40% | GrowthEPS=+23.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.13 | Chg30d=-7.65% | Revisions=+40% | GrowthEPS=-12.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +67% (up=6, down=0)